Regen BioPharma Inc (RGBP)

[Carter]

Biotech Companies Focused on Cancer Research are Being Acquired at Massive Valuations
https://www.prnewswire.com/news-releases/biotech-companies-focused-on-cancer-research-are-being-acquired-at-massive-valuations-300961695.html

LOS ANGELES, Nov. 20, 2019 /PRNewswire/ -- The global biotech market will surpass $775 billion USD by 2024; according to a new research report by Global Market Insights, Inc.

This opinion is echoed by portfolio managers who think the industry has plenty of room to run. As more useful IP is developed by some of the top players, newcomers are also making a dent, positioning themselves for further M&A's which are rising in popularity year over year.

Biotech continues to grow at a rapid pace, so it makes sense then that the industry would be attracting all kinds of new investors to both the industry giants, and small-mid cap companies alike.

Ivo Staijen, manager of the HBM Global Biotechnology fund, is also feeling optimistic about the sector's prospects, pointing out the number of constituents in the Nasdaq Biotechnology index has increased sharply in recent years.

"Most investors have exposure to the large pharmaceutical giants but from a value creation perspective they should be invested in earlier-stage companies too. Biotechnology is the backbone of innovation these days," says Staijen

Start With IP
The IP that drives biotech may be one of the easy entry points for early investors to look at.

Going In On Niche Market Segments
If cancer biotech can reach the kind of massive revenue numbers the current data suggests, some of these newcomers may become the future giants of the industry that come to define the future of biotech, medical research and pharmaceutical